Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Compounding And Medspa topic
No spam. Unsubscribe anytime.
BRN flags med-spa IV clinics for possible unlawful compounding, plans education and cross-board outreach
Summary
BRN staff told the Impact Committee that state pharmacy compounding rules limit "immediate use" compounding to life-or-limb scenarios and that many RNs/APRNs and outpatient IV/med-spa clinics may be unaware their routine admixing meets the legal definition of compounding; the board plans education, partner outreach and will track complaints.
The California Board of Registered Nursing told its Impact Committee April 9 that state pharmacy compounding regulations restrict "immediate use" compounding to situations where failing to administer a compounded sterile preparation would likely result in "loss of life or intense suffering," and that the pharmacy board's definition therefore excludes routine outpatient med-spa or IV-hydration mixing, which BRN staff said many licensees and clinics have been doing without recognizing the regulatory limit.
Lori Melby, the BRN's executive officer, cited the pharmacy regulation (16 CCR 1736.1) and summarized the standard: "Any such compounding shall be only in such quantity as is necessary to meet the immediate need of the patient ... delivered and administered to that single patient," language BRN staff said does not cover typical med-spa practices. Melby added that pharmacy board rules and federal USP standards underlie that interpretation and that the BRN's statute also contains a statement that RNs cannot compound.
"It was asked by our chair to bring this forward and provide that information to this group," Melby said, explaining the board's objective is educational outreach and clarity for licensees rather than immediate punitive action. The BRN discussed options including: a listserv message to all licensees, updates to the BRN website and social-media messaging, coordination with other Department of Consumer Affairs boards (pharmacy, medical board, etc.), and referral to the pharmacy board for matters that fall under pharmacy regulation.
Committee members and public commenters raised concerns about hospitals and clinical settings where bedside admixing has long been routine; staff acknowledged the practical implications and said any legislative fix would probably require coordinated statutory changes to pharmacy law as well as BRN statute. Melby said the board has delayed rolling out public messaging until the committee and partner boards can provide guidance and possible alternatives (for example, partnering with compounding pharmacies or clarifying permissible admixing practices).
What this means for clinicians: According to staff, routine bedside combination of two drugs (a common example is drawing up "clear to cloudy" insulin) can meet a technical definition of compounding under current pharmacy rules and therefore be outside RN/APRN scope unless handled through a lawful compounding pathway. BRN staff urged licensees to review forthcoming educational materials and to consult pharmacy law and their employers if uncertain.
